Neuraminidase Inhibitors for Treatment of Influenza A and B Infections
Please note: An erratum has been published for this article. To view the erratum, please click here.
The following CDC staff members prepared this report:
Andrea G. Winquist, M.D.
Division of Viral and Rickettsial Diseases
Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine has been available in the United States since 1976, and rimantadine has been available since 1993. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged greater than or equal to 12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged greater than or equal to 18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at <http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm> or at the MMWR website at <http://www2.cdc.gov/mmwr/>.
Uncomplicated influenza is characterized by the abrupt onset of constitutional and respiratory signs and symptoms (e.g., fever, myalgia, headache, severe malaise, nonproductive cough, sore throat, and rhinitis) (1,2). However, in some persons, influenza can exacerbate underlying medical conditions (e.g., pulmonary or cardiac disease) or lead to secondary bacterial pneumonia or primary influenza viral pneumonia (1). Epidemics of influenza occur during the winter months nearly every year and are responsible for an average of approximately 20,000 deaths per year in the United States (3,4). The main method for preventing influenza and its more severe complications is immunoprophylaxis with inactivated (i.e., killed-virus) vaccine (1). Influenza-specific antiviral drugs for chemoprophylaxis or therapy are an important adjunct to vaccine, but they are not a substitute for influenza vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine hydrochloride and rimantadine hydrochloride as well as two recently approved neuraminidase inhibitors, zanamivir and oseltamivir.
Amantadine and rimantadine are chemically related antiviral drugs active against influenza A viruses but not influenza B viruses. After influenza A viruses enter cells, these drugs inhibit the uncoating of influenza A viruses by blocking the ion-channel activity of the viral M2 protein (5-10). Amantadine was approved in 1976 for treatment and prophylaxis of influenza type A infection in adults and children aged greater than or equal to 1 year. Rimantadine was approved in 1993 for treatment and prophylaxis of influenza type A infection in adults. For children, rimantadine was approved only for prophylaxis; however, many experts consider rimantadine appropriate for treatment of influenza A in children (1). (For information on the use of amantadine and rimantadine, see Recommendations for the Use of Antiviral Agents for Influenza A in the Advisory Committee on Immunization Practices 1999 recommendations on influenza prevention and control .)
Zanamivir and oseltamivir, both approved in 1999 by the U.S. Food and Drug Administration, are members of a new class of antiviral agents that selectively inhibit the neuraminidase of both influenza A and B viruses. Neuraminidase cleaves terminal sialic acid residues from carbohydrate moieties on the surfaces of host cells and influenza virus envelopes; this process promotes the release of progeny viruses from infected cells (11,12). Neuraminidase inhibitors are analogues of sialic acid. Their proposed mechanism of action is to block the active site of neuraminidase and leave uncleaved sialic acid residues on the surfaces of host cells and influenza viral envelopes. Viral hemagglutinin binds to the uncleaved sialic acid residues; the result is viral aggregation at the host cell surface and a reduction in the amount of virus that is released and can infect other cells (13).
USE OF NEURAMINIDASE INHIBITORS FOR TREATMENT OF INFLUENZA A AND B INFECTIONS
Laboratory Diagnosis of Influenza
The appropriate treatment of patients with viral respiratory illness depends on accurate and timely diagnosis. The early diagnosis of influenza can help reduce the inappropriate use of antibiotics and provide the option of using antiviral therapy. Influenza surveillance information as well as diagnostic testing (e.g., viral culture and rapid tests for influenza) can aid clinical judgment and help guide treatment decisions.
Influenza surveillance by state and local health departments and CDC can provide information about the presence of influenza viruses in the community. Surveillance can also identify the predominant circulating types, subtypes, and strains of influenza.
Several commercial rapid diagnostic tests are available that can be used by laboratories in outpatient settings to detect influenza viruses within 30 minutes (2). Some of these rapid tests detect only influenza A viruses, whereas other rapid tests detect both influenza A and B viruses but do not distinguish between the two types. Additional commercial diagnostic tests are available for use by laboratories performing tests of high complexity (2).
Despite the availability of rapid diagnostic tests, the collection of clinical specimens for viral culture is important because only culture isolates can provide specific information on circulating influenza subtypes and strains. This information is needed to compare current circulating influenza strains and vaccine strains, to guide decisions about influenza treatment and prophylaxis, and to formulate vaccine for the coming year. Virus isolates also are needed to monitor the emergence of antiviral resistance.
Indications for Use of Zanamivir and Oseltamivir
Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in adults and adolescents aged greater than or equal to 12 years who have been symptomatic for no more than 2 days.* This indication was based on studies in which the predominant influenza infections were influenza A and a limited number of patients with influenza B were also enrolled (14). Zanamivir is not approved for use in children aged less than 12 years.
Oseltamivir is approved for treatment of uncomplicated acute illness caused by influenza infection in adults agedgreater than or equal to 18 years who have been symptomatic for no more than 2 days.** This indication was based on studies of naturally occurring influenza in which the predominant infection was influenza A and influenza challenge studies in which the antiviral activity of oseltamivir was supported for influenza A and B (15). Oseltamivir is not approved for use in children (aged less than 18 years).
When administered within 2 days of illness onset among otherwise healthy adults, zanamivir and oseltamivir can reduce by approximately 1 day the duration of moderate or severe symptoms of uncomplicated influenza (16-23). The evidence for the efficacy of both drugs is based primarily on data from patients with fever greater than or equal to 37.8 C (100 F) at the time therapy was started.
More clinical data are available concerning the effectiveness of zanamivir and oseltamivir for treatment of influenza A infection than for treatment of influenza B infection. However, in vitro data (24-29) and data from treatment in mice and ferrets (26,27,30,31) document that zanamivir and oseltamivir have activity against influenza B viruses. Limited data from clinical trials of zanamivir (17,32) and from studies of oseltamivir treatment of experimental influenza B infections (33) also suggest that zanamivir and oseltamivir are effective for treatment of infections caused by influenza B viruses.
Neither zanamivir nor oseltamivir has been demonstrated to be effective in preventing serious influenza-related complications, such as bacterial or viral pneumonia or exacerbation of chronic diseases. Data are limited and inconclusive concerning the effectiveness of zanamivir for treatment of influenza in persons at high risk for serious complications of influenza (17,18,20,34). No published data are available concerning the effectiveness of oseltamivir for treatment of influenza in high-risk populations. No clinical data are available regarding the safety or efficacy of zanamivir or oseltamivir for pregnant women.
Zanamivir and oseltamivir are not approved for prophylactic use. However, recently published studies of zanamivir and oseltamivir for prophylaxis of influenza in community settings demonstrated both drugs to be similarly effective in preventing laboratory-confirmed clinical influenza with fever (efficacy: zanamivir, 84%; oseltamivir, 82%) (35,36). Experience with prophylactic use of these agents in institutional settings is limited (37-39). Vaccination remains the best prophylaxis for influenza.
Administration of Zanamivir and Oseltamivir
The recommended dosage of zanamivir for treatment of influenza in persons aged greater than or equal to 12 years is two inhalations (one 5-mg blister per inhalation for a total dose of 10 mg) twice daily (approximately 12 hours apart) for 5 days (14).
The recommended dosage of oseltamivir for treatment of influenza in persons aged greater than or equal to 18 years is 75 mg orally twice daily for 5 days (15). A reduction in dosage is recommended for persons with creatinine clearance less than 30 mL/min (see Persons with Impaired Renal Function) (15).
Zanamivir is available as a dry powder that is self-administered via oral inhalation by using a plastic device included in the package with the medication. Although the plastic device is similar to devices used to deliver some asthma medications, use of this device should be restricted to delivery of zanamivir (40). Delivery of the medication requires loading of a medication disk into the plastic device each day. Patients will benefit from instruction and demonstration of proper use of the device. Zanamivir is packaged in a disk with four blisters of medication, each containing a powder mixture of 5 mg of zanamivir and 20 mg of lactose (14).
Oseltamivir is administered orally. It is available as 75-mg capsules (15).
In studies of healthy volunteers, approximately 7%-21% of the orally inhaled zanamivir dose reached the lungs, and 70%-87% was deposited in the oropharynx (41,42). Approximately 4%-17% of the total amount of orally inhaled zanamivir is systemically absorbed. Systemically absorbed zanamivir has a half-life of 2.5-5.1 hours and is excreted unchanged in the urine. Unabsorbed drug is excreted in the feces (14,43).
Approximately 80% of orally administered oseltamivir is absorbed systemically (33). Absorbed oseltamivir is metabolized to GS4071 (oseltamivir carboxylate), the active neuraminidase inhibitor, primarily by hepatic esterases. GS4071 has a half-life of 6-10 hours and is excreted in the urine by glomerular filtration and tubular secretion via the anionic pathway (15,44). Unmetabolized oseltamivir also is excreted in the urine by glomerular filtration and tubular secretion (44).
Persons with Impaired Renal Function
Limited data are available regarding the safety and efficacy of zanamivir for patients with impaired renal function. Among patients with renal failure who were administered a single intravenous dose of zanamivir in prelicensure studies, decreases in renal clearance and increases in half-life and systemic exposure to zanamivir were observed (14,45). However, a small number of healthy volunteers who were administered high doses of intravenous zanamivir tolerated systemic levels of zanamivir that were much higher than those resulting from administration of zanamivir by oral inhalation at the recommended dose (43,46). On the basis of these considerations, the manufacturer recommends no dose adjustment for inhaled zanamivir for a 5-day course of treatment for patients with either mild-to-moderate or severe impairment in renal function (45).
Among patients with impaired renal function, serum concentrations of oseltamivir carboxylate increase with declining renal function (15,33). A reduction of the dose of oseltamivir to 75 mg once daily is recommended for patients with creatinine clearance less than 30 mL/min (15). No data are available concerning the safety or efficacy of oseltamivir in patients with creatinine clearance less than 10 mL/min.
Persons with Liver Disease
The pharmacokinetics of zanamivir and oseltamivir have not been studied in patients with impaired hepatic function (14,15).
Side Effects and Adverse Reactions
In clinical treatment studies of inhaled zanamivir, the frequencies of adverse events were similar for persons receiving inhaled zanamivir and those receiving placebo (i.e., inhaled lactose vehicle alone) (14,16-21,47). The most common adverse events reported by both groups were diarrhea; nausea; sinusitis; nasal signs and symptoms; bronchitis; cough; headache; dizziness; and ear, nose, and throat infections (14,16,17,19,20). Each of these symptoms was reported by less than 5% of persons in the clinical treatment studies combined (14). Caution is advised if zanamivir is prescribed for patients with underlying chronic respiratory disease. In a phase I study of persons with mild or moderate asthma who did not have influenza-like illness, 1 of 13 patients experienced bronchospasm following administration of zanamivir (14). In addition, preliminary results of a study of zanamivir treatment of influenza-like illness among persons with asthma or chronic obstructive pulmonary disease indicated that more patients receiving zanamivir than placebo experienced a greater than 20% decline in forced expiratory volume in 1 second (FEV1) or peak expiratory flow rates after treatment (14). Patients with asthma or chronic obstructive pulmonary disease are advised to a) have a fast-acting inhaled bronchodilator available when inhaling zanamivir and to b) stop using zanamivir and contact their physician if they develop difficulty breathing (14). Nausea and vomiting were reported more frequently among persons receiving oseltamivir for treatment (nausea without vomiting, approximately 10%; vomiting, approximately 9%) than among persons receiving placebo (nausea without vomiting, approximately 6%; vomiting, approximately 3%) (15,22,23,48). However, few persons enrolled in the clinical treatment trials of oseltamivir discontinued treatment because of these symptoms (15). Nausea and vomiting might be less severe if oseltamivir is taken with food (15,48).
Although clinical data are limited regarding drug interactions with zanamivir, no known drug interactions with zanamivir have been reported, and no clinically important drug interactions have been predicted on the basis of in vitro data and data from studies in rats (14,49). Zanamivir does not affect the cytochrome P450 isoenzymes in human liver microsomes (14,49) and is not expected to alter the metabolism of other drugs metabolized by these enzymes. Treatment with zanamivir has not been found to impair the immunologic response to influenza vaccine (14,50). No published data are available concerning the safety or efficacy of coadministering amantadine or rimantadine with zanamivir.
Limited clinical data are available regarding drug interactions with oseltamivir. Because oseltamivir and its active metabolite, GS4071, are excreted in the urine by glomerular filtration and tubular secretion via the anionic pathway, a potential exists for interaction with other agents excreted by this pathway. For example, coadministration of oseltamivir and probenecid resulted in a reduction in the clearance of GS4071 by approximately 50% and a corresponding approximate twofold increase in the plasma levels of GS4071 (15,44). Oseltamivir and GS4071 are not substrates for the cytochrome P450 isoenzymes and are not expected to alter the metabolism of other drugs metabolized by these enzymes (15). No published data are available concerning the safety or efficacy of coadministering amantadine or rimantadine with oseltamivir.
Antiviral Drug Resistance
Resistance to zanamivir and oseltamivir can be induced in influenza A and B viruses in vitro (51-58), but induction of resistance requires several passages in cell culture. By contrast, resistance to amantadine and rimantadine in vitro can be induced with fewer passages in cell culture (10,59). Whether these in vitro findings indicate that clinical drug resistance will occur less frequently with zanamivir and oseltamivir than with amantadine and rimantadine is unknown. Development of viral resistance to zanamivir and oseltamivir during treatment has been identified but does not appear to be frequent (15,18,60,61). Currently available diagnostic tests are not optimal for detecting clinical resistance, and better tests as well as more testing are needed before firm conclusions can be reached. Postmarketing surveillance for neuraminidase inhibitor-resistant influenza viruses is planned.
Comparison of Current Antiviral Agents
Zanamivir, oseltamivir, amantadine, and rimantadine vary in terms of the types of influenza viruses they inhibit, route of administration, and approved use in different age groups (Table 1). No studies have directly compared the effectiveness of these drugs for treatment of influenza A; however, available information indicates that all four agents are roughly comparable in reducing the duration of uncomplicated acute illness due to influenza A when treatment is started shortly after onset of symptoms. None of the four agents has been shown to decrease serious complications of influenza (e.g., pneumonia, hospitalization). Information about the use of zanamivir and oseltamivir among persons at high risk for influenza complications is limited.
The side effects and cost of zanamivir and oseltamivir differ from those of amantadine and rimantadine. Central nervous system side effects (e.g., nervousness, anxiety, difficulty concentrating, and lightheadedness) have been associated with amantadine and to a lesser extent with rimantadine (1). Amantadine has also been associated with an increased incidence of seizures among patients with a history of seizure disorders (1). Whether rimantadine is associated with an increased incidence of seizures among patients with a history of seizure disorders has not been adequately evaluated (1). Central nervous system side effects have been infrequently reported among patients taking zanamivir and oseltamivir (14,15). Because some persons with underlying asthma or chronic obstructive pulmonary disease have experienced reduced FEV1 or peak expiratory flow rate following treatment with zanamivir, caution is advised if zanamivir is used by patients with underlying chronic respiratory disease. Oseltamivir has been associated with nausea and vomiting. The dose of amantadine, rimantadine, and oseltamivir must be reduced for patients with renal failure. Finally, zanamivir and oseltamivir are more expensive than rimantadine, which is more expensive than amantadine (62,63).
Amantadine has been available since 1976, and rimantadine has been available since 1993; both drugs have been extensively used for treatment and prophylaxis of influenza A. Zanamivir and oseltamivir offer new options for treatment of influenza. Antiviral agents for influenza -- including amantadine, rimantadine, zanamivir, and oseltamivir -- are an adjunct to vaccine and are not a substitute for vaccine. Immunoprophylaxis with inactivated (i.e., killed-virus) vaccine remains the principal means for reducing influenza-related morbidity and death.
* No data are available to support zanamivir's efficacy if treatment is initiated greater than 48 hours after onset of illness (14).
** No data are available to support oseltamivir's efficacy if treatment is initiated greater than 40 hours after onset of illness (15).
Note: To print large tables and graphs users may have to change their printer settings to landscape and use a small font size.
TABLE 1. Comparison of antiviral agents for influenza
NOTE:Amantadine manufacturers include Endo Pharmaceuticals (Symetrel® -- tablet and syrup); Invamed and Rosemont (Amantadine HCL -- capsule); and Alpharma, Copley Pharmaceutical, HiTech Pharma, Mikart, Morton Grove, and Pharmaceutical Associates (Amantadine HCL -- syrup). Rimantadine is manufactured by Forest Laboratories (Flumadine® -- tablet and syrup). Zanamivir is manufactured by Glaxo Wellcome (Relenza® -- for inhalation). Oseltamivir is manufactured by Hoffman-La Roche Inc. (Tamiflu® -- capsule).
* Zanamivir is administered by using a specially designed plastic oral inhalation device (Diskhaler®). The device and instructions on its use are included in the package with the medication.
Return to top.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.
Page converted: 12/15/1999
This page last reviewed 5/2/01